Dear Sir or Madam:
The Plasma Protein Therapeutics Association ("PPTA" or "Association") commends the Food and Drug Administration ("FDA" or "Agency") for addressing the critical issue of drug shortages through its February 2012 draft Guidance to industry, "Notification to FDA of Issues that May Result in a Prescription Drug or Biological Product Shortage" ("Draft Guidance").
The Plasma Protein Therapeutics Association (PPTA) recognizes World Hemophilia Day, an international event sponsored by the World Federation for Hemophilia (WFH) and designed to raise awareness of people living with inherited bleeding disorders.
ANNAPOLIS, MD – Plasma Protein Therapeutics Association (PPTA) joins over 300 organizations in 56 countries in recognizing International Rare Disease Day. This event, now in its fifth year, seeks to raise awareness among the general public and decision makers about rare diseases, impacting lives all over the globe.
Dear PPTA Stakeholders,
PPTA is pleased to announce that, as of today, reporting of data on the U.S. supply of certain plasma protein therapies has resumed.
Dear PPTA Stakeholders,
PPTA's North America data program was established in 1998 in response to a specific recommendation of the Advisory Committee on Blood Safety and Availability (ACBSA).
ANNAPOLIS, MD - The Plasma Protein Therapeutics Association (PPTA) honored California State Assemblymember Toni Atkins (D) of San Diego as State Legislator of the Year for 2011-2012.
ANNAPOLIS, MD - The Plasma Protein Therapeutics Association (PPTA) attended a U.S. Food and Drug Administration (FDA)–sponsored workshop to address growing concerns regarding drug shortages in certain sectors of the pharmaceutical industry September 26.
This month, Florida and California are recognizing "Plasma Protein Therapies Month," by raising awareness for the valuable contributions of plasma donors and for the rare, genetic diseases treated with the therapies that are made possible through plasma donation.
BRUSSELS, BELGIUM - The Plasma Protein Therapeutics Association (PPTA) welcomes the findings of the ConQuaestor report on the financing of Sanquin, the Dutch National Fractionator.
ANNAPOLIS, MD - The Plasma Protein Therapeutics Association (PPTA) believes the Internal Revenue Services' issuance of temporary and proposed regulations implementing the annual pharmaceutical fee undermines patients with rare diseases and fails to take into account concerns expressed by leading consumer organizations and Congress.
